GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cognetivity Neurosciences Ltd (OTCPK:CGNSF) » Definitions » EPS (Diluted)

CGNSF (Cognetivity Neurosciences) EPS (Diluted) : $-0.07 (TTM As of Oct. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Cognetivity Neurosciences EPS (Diluted)?

Cognetivity Neurosciences's Earnings per Share (Diluted) for the three months ended in Oct. 2023 was $-0.02. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2023 was $-0.07.

Cognetivity Neurosciences's EPS (Basic) for the three months ended in Oct. 2023 was $-0.02. Its EPS (Basic) for the trailing twelve months (TTM) ended in Oct. 2023 was $-0.07.

Cognetivity Neurosciences's EPS without NRI for the three months ended in Oct. 2023 was $-0.02. Its EPS without NRI for the trailing twelve months (TTM) ended in Oct. 2023 was $-0.08.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Cognetivity Neurosciences EPS (Diluted) Historical Data

The historical data trend for Cognetivity Neurosciences's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cognetivity Neurosciences EPS (Diluted) Chart

Cognetivity Neurosciences Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23
EPS (Diluted)
Get a 7-Day Free Trial -0.08 -0.05 -0.02 -0.14 -0.06

Cognetivity Neurosciences Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.02 -0.02 -0.02 -0.02

Competitive Comparison of Cognetivity Neurosciences's EPS (Diluted)

For the Health Information Services subindustry, Cognetivity Neurosciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cognetivity Neurosciences's PE Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cognetivity Neurosciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Cognetivity Neurosciences's PE Ratio falls into.



Cognetivity Neurosciences EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Cognetivity Neurosciences's Diluted EPS for the fiscal year that ended in Jan. 2023 is calculated as

Diluted EPS (A: Jan. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-5.539-0)/98.398
=-0.06

Cognetivity Neurosciences's Diluted EPS for the quarter that ended in Oct. 2023 is calculated as

Diluted EPS (Q: Oct. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-1.486-0)/88.369
=-0.02

EPS (Diluted) for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cognetivity Neurosciences  (OTCPK:CGNSF) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Cognetivity Neurosciences EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Cognetivity Neurosciences's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Cognetivity Neurosciences Business Description

Traded in Other Exchanges
N/A
Address
800 West Pender Street, Suite 1430, Vancouver, BC, CAN, V6C 2V6
Cognetivity Neurosciences Ltd is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial, and consumer environments for potentially allowing early diagnosis of dementia. The Company is considered operating in one segment for development of the ICA platform. Its geographical areas include Canada, United Kingdom and Dubai.

Cognetivity Neurosciences Headlines

From GuruFocus

The Most Innovative Healthcare AI Developments of 2019

By ACCESSWIRE AccessWire 04-12-2019